OBJECTIVE	To compare , in a post hoc analysis of a phase III trial , the maximum recommended doses of fesoterodine ( 8 mg ) and tolterodine ( 4 mg ) for improving overactive bladder ( OAB ) symptoms and health-related quality of life ( HRQoL ) , as fesoterodine effectively reduces OAB symptoms vs placebo .\